Live Breaking News & Updates on Insider Activity At Eyepoint Pharmaceuticals

Stay updated with breaking news from Insider activity at eyepoint pharmaceuticals. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Monashee Investment Management LLC Takes $4.04 Million Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Monashee Investment Management LLC bought a new stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 175,000 shares of the company’s stock, valued at approximately $4,044,000. EyePoint Pharmaceuticals accounts for about 0.7% of Monashee […] ....

China , Robertw-baird , Davidr-guyer , Securities-exchange-commission , Quarter-for-eyepoint-pharmaceuticals , Investment-advisers , Deutsche-bank , Eyepoint-pharmaceuticals-company-profile , China-universal-asset-management-co , Eyepoint-pharmaceuticals , Eyepoint-pharmaceuticals-inc

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Consensus Recommendation of "Buy" from Analysts

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Consensus Recommendation of "Buy" from Analysts
wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.

Robertw-baird , York-mellon-corp , Eyepoint-pharmaceuticals-company-profile , Securities-exchange-commission , Eyepoint-pharmaceuticals-stock , Jpmorgan-chase-co , Analyst-recommendations-for-eyepoint-pharmaceuticals , Insider-activity-at-eyepoint-pharmaceuticals , Eyepoint-pharmaceuticals-inc , Eyepoint-pharmaceuticals , Hedge-funds-weigh-in-on-eyepoint-pharmaceuticals

Analysts Set EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Target Price at $34.00

Analysts Set EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Target Price at $34.00
dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.

Securities-exchange-commission , Hermes-inc , Insider-activity-at-eyepoint-pharmaceuticals , Eyepoint-pharmaceuticals-inc , Franklin-resources-inc , Analyst-recommendations-for-eyepoint-pharmaceuticals , Nasdaq , Eyepoint-pharmaceuticals-price-performance , News-ratings-for-eyepoint-pharmaceuticals-daily , Jennison-associates , Jpmorgan-chase-co

EyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Gap Down to $21.53

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Get Free Report) gapped down before the market opened on Wednesday . The stock had previously closed at $21.53, but opened at $20.26. EyePoint Pharmaceuticals shares last traded at $20.84, with a volume of 50,221 shares changing hands. Analyst Ratings Changes Several research analysts recently commented on the company. Mizuho […] ....

Darioa-paggiarino , Nasdaq , News-ratings-for-eyepoint-pharmaceuticals-daily , Eyepoint-pharmaceuticals-company-profile , Eyepoint-pharmaceuticals , Jump-financial , Scotia-capital-inc , Insider-activity-at-eyepoint-pharmaceuticals , Eyepoint-pharmaceuticals-inc , Jpmorgan-chase-co , Securities-exchange-commission

Legato Capital Management LLC Sells 18,054 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Legato Capital Management LLC trimmed its holdings in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Free Report) by 23.3% during the fourth quarter, HoldingsChannel reports. The fund owned 59,347 shares of the company’s stock after selling 18,054 shares during the quarter. Legato Capital Management LLC’s holdings in EyePoint Pharmaceuticals were worth $1,372,000 at the end […] ....

Darioa-paggiarino , Eyepoint-pharmaceuticals-company-profile , Eyepoint-pharmaceuticals-stock-down , Legato-capital-management , Goldman-sachs-group-inc , Insider-activity-at-eyepoint-pharmaceuticals , Jpmorgan-chase-co , Vanguard-group-inc , Eyepoint-pharmaceuticals-inc , News-ratings-for-eyepoint-pharmaceuticals-daily , Nasdaq